title: Involvement of the GABAergic system in the neuroprotective and sedative effects of acacetin 7-O-glucoside in rodents.
abstract: OBJECTIVE
  Characterization of sedative, possible anticonvulsant, and protective effects of Acacetin-7-O-glucoside (7-ACAG).
  
  
  METHODS
  7-ACAG was separated and its purity was analyzed. Its sedative and anti-seizure effects (1, 10, 20, and 40 mg/kg) were evaluated in male mice. Synaptic responses were acquired from area CA1 of hippocampal slices obtained from male Wistar rats. Rats were subjected to stereotaxic surgeries to allow Electroencephalographic (EEG) recordings. Functional recovery was evaluated by measuring the time rats spent in completing the motor task. Then the rats were subjected to right hemiplegia and administered 7-ACAG (40 mg/kg) 1 h or 24 h after surgery. Brains of each group of rats were prepared for histological analysis.
  
  
  RESULTS
  Effective sedative doses of 7-ACAG comprised those between 20 and 40 mg/kg. Latency and duration of the epileptiform crisis were delayed by this flavonoid. 7-ACAG decreased the synaptic response in vitro, similar to Gamma-aminobutyric acid (GABA) effects. The flavonoid facilitated functional recovery. This data was associated with preserved cytoarchitecture in brain cortex and hippocampus.
  
  
  CONCLUSIONS
  7-ACAG possesses anticonvulsive and sedative effects. Results suggest that GABAergic activity and neuroprotection are involved in the mechanism of action of 7-ACAG and support this compound's being a potential drug for treatment of anxiety or post-operative conditions caused by neurosurgeries.
authors.affiliation: Department of Neurobiology, National Institute of Psichiatry, D.F., México.
authors.forename: Javier
authors.initials: J
authors.lastname: Gálvez
authors.affiliation: Laboratory of Phytopharmacology, National Institute of Psichiatry, D.F., México.
authors.forename: Rosa
authors.initials: R
authors.lastname: Estrada-Reyes
authors.affiliation: Laboratory of Neuropharmacology, National Institute of Psichiatry, D.F., México.|National Institute of Psichiatry, D.F, Ramón de la Fuente Muñíz, Calzada México-Xochimilco 101, Col. San Lorenzo Huipulco, Delegación Tlalpan, 14370 México, D.F., México.
authors.forename: Gloria
authors.initials: G
authors.lastname: Benítez-King
authors.affiliation: Laboratory of Phytopharmacology, National Institute of Psichiatry, D.F., México.
authors.forename: Gabriela
authors.initials: G
authors.lastname: Araujo
authors.affiliation: Unit of Medical Research in Neurologic Deseases (UIMEN), Hospital de Especialidades, Medical National Center Century XXI, Mexican Institute of Social Security, Av. Cuauhtémoc #330, Col. Doctores, Del. Cuauhtémoc, México, D.F., México.
authors.forename: Sandra
authors.initials: S
authors.lastname: Orozco
authors.affiliation: Laboratory of Neurophysiology of Control and Regulation, National Institute of Psichiatry, D.F., México.
authors.forename: Rodrigo
authors.initials: R
authors.lastname: Fernández-Mas
authors.affiliation: Departament of Bioelectronics, National Institute of Psichiatry, D.F., México.
authors.forename: Salvador
authors.initials: S
authors.lastname: Almazán
authors.affiliation: Department of Neurobiology, National Institute of Psichiatry, D.F., México.
authors.forename: Eduardo
authors.initials: E
authors.lastname: Calixto
mesh_terms: D000818:Animals; D000927:Anticonvulsants / Q000737:chemistry / Q000302:isolation & purification / Q000494:pharmacology*; D056547:CA1 Region, Hippocampal / Q000187:drug effects / Q000502:physiology; D002540:Cerebral Cortex / Q000187:drug effects / Q000503:physiopathology; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D005419:Flavonoids / Q000737:chemistry / Q000302:isolation & purification / Q000494:pharmacology*; D005960:Glucosides / Q000737:chemistry / Q000302:isolation & purification / Q000494:pharmacology*; D006429:Hemiplegia / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology; D006993:Hypnotics and Sedatives / Q000737:chemistry / Q000302:isolation & purification / Q000494:pharmacology*; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology; D018696:Neuroprotective Agents / Q000737:chemistry / Q000302:isolation & purification / Q000494:pharmacology*; D017208:Rats, Wistar; D020127:Recovery of Function / Q000187:drug effects / Q000502:physiology; D012640:Seizures / Q000188:drug therapy / Q000503:physiopathology; D046509:Tissue Culture Techniques; D005680:gamma-Aminobutyric Acid / Q000378:metabolism*
chemical_list: D000927:Anticonvulsants; D005419:Flavonoids; D005960:Glucosides; D006993:Hypnotics and Sedatives; D018696:Neuroprotective Agents; C477955:acacetin-7-O-glucoside; D005680:gamma-Aminobutyric Acid
keywords: Flavonoids; GABAA; functional recovery; hemiplegia